<DOC>
	<DOCNO>NCT00019006</DOCNO>
	<brief_summary>RATIONALE : Vaccines make mutate ra peptide may make body build immune response kill tumor cell . PURPOSE : Phase I trial study effectiveness vaccine contain mutate ra peptide immune adjuvant treat patient colon , pancreatic , lung cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Colon , Pancreatic , Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether endogenous cellular humoral immunity tumor-specific mutate ra protein present patient colorectal , pancreatic , lung cancer . II . Determine whether vaccination synthetic peptide correspond tumor 's ras mutation combine Detox-B adjuvant induce boost cellular immunity particular mutation patient population . III . Determine type characteristic cellular immunity generate patient treated regimen . IV . Determine tolerance toxicity spectrum peptide give Detox-B adjuvant patient . V. Determine immune response associate peptide dose patient . VI . Assess tumor response may occur treatment patient treat regimen . PROTOCOL OUTLINE : This dose-escalation study . Patients receive tumor-specific mutate ra peptide combine Detox-B adjuvant subcutaneously monthly 3 month . Treatment continue absence disease progression unacceptable toxicity . Patients stable respond disease specific immunologic response may receive 3 additional monthly vaccination . Cohorts 3-6 patient receive escalate dos tumor-specific mutate ra peptide combine Detox-B adjuvant maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 33 patient ( 12 adjuvant set ) accrue study within 12 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Detox adjuvant</mesh_term>
	<criteria>1 . Histopathologically confirm diagnosis Langerhans cell histiocytosis accord criterion define Histiocyte Society Demonstration CD1a antigenic determinant surface lesional cell ( immunocytology immunohistology ) Birbeck granules lesional cell electron microscopy 2 . Considered risk low risk accord follow criterion : 1 . Multisystem risk disease , define involvement one risk organ ( i.e. , hematopoietic system , liver , spleen , lung ) No singlesystem lung involvement 2 . Multisystem lowrisk disease Multiple organs involve without involvement risk organs 3 . Singlesystem disease Multifocal bone disease ( i.e. , lesion 2 different bone ) Localized special site involvement , CNSrisk lesions intracranial soft tissue extension vertebral lesion intraspinal soft tissue extension Vault lesion regard CNSrisk lesion PROTOCOL ENTRY CRITERIA : Disease Characteristics Histologically document solid tumor potentially express mutant ra Stage II/III adenocarcinoma lung follow surgery radiotherapy Limited extensive small cell lung cancer complete remission Dukes ' C colorectal cancer follow appropriate adjuvant chemotherapy Fully resect recurrent colorectal carcinoma Fully resect pancreatic carcinoma Tumor tissue available determination ra mutation Paraffin block fresh tissue Specific point mutation codon 12 require , include : Glycine cysteine Glycine aspartic acid Glycine valine Tumor tissue available preparation tumor cell line tumor lymph node tissue expansion tumor infiltrate lymphocyte vitro laboratory study prefer No history CNS metastases Prior/Concurrent Therapy Biologic therapy : At least 4 week since prior immunotherapy recover Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy recover Endocrine therapy : At least 4 week since prior steroid recover Radiotherapy : At least 4 week since prior radiotherapy recover Surgery : See Disease Characteristics Not specify Patient Characteristics Age : Over 18 Performance status : ECOG 01 Life expectancy : More 3 month Hematopoietic : WBC least 3,000/mm3 Lymphocyte count least 600/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL ALT AST great 4 time normal Hepatitis B C surface antigen negative Renal : Creatinine great 2.0 mg/dL Cardiovascular : No active ischemic heart disease ( New York Heart Association class III/IV ) No myocardial infarction within 6 month No history arrhythmia No clinical symptom suggest cardiac insufficiency Pulmonary : No clinical symptom suggest pulmonary insufficiency Immunologic : Responsive anergy skin test mumps , trichophyton , candida antigen HIV negative No autoimmune disease , e.g . : Systemic lupus erythematosus Multiple sclerosis Ankylosing spondylitis Other : No active infection require antibiotic No history malignancy except curatively treat basal cell skin carcinoma curatively treat carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>adult solid tumor</keyword>
	<keyword>body system/site cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>colon cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>gastrointestinal cancer</keyword>
	<keyword>genetic condition</keyword>
	<keyword>limited stage small cell lung cancer</keyword>
	<keyword>lung cancer</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>small cell lung cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage III non-small cell lung cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>stage IVA pancreatic cancer</keyword>
	<keyword>stage IVB pancreatic cancer</keyword>
	<keyword>stage , colon cancer</keyword>
	<keyword>stage , non-small cell lung cancer</keyword>
	<keyword>stage , pancreatic cancer</keyword>
	<keyword>stage , rectal cancer</keyword>
	<keyword>stage , small cell lung cancer</keyword>
	<keyword>thorax/respiratory cancer</keyword>
</DOC>